GAO Just Ruled That Firing Your Grant Staff Is Not a Legal Excuse for Not Spending the Money

For eighteen months, the standard explanation for why federal grant money was not moving has been administrative: the reviewers are gone, the program officers are gone, the people who push the button are gone, and so the button does not get pushed. It was offered as a regrettable fact of nature, like weather.

On October 7, 2026, the Government Accountability Office published Decision B-337872 and said, in effect: no. That is a choice, and choices have legal consequences.

The decision concerns the Agency for Healthcare Research and Quality, which received a $369 million lump-sum appropriation for fiscal year 2025 and obligated roughly $290 million of it, leaving more than $78 million on the table when the year closed on September 30, 2025. GAO concluded that the shortfall was not administrative drift. It was an impoundment under the Impoundment Control Act of 1974, executed without the special message to Congress that the Act requires, and therefore unlawful.

The dollar figure is modest by federal standards. The reasoning is not. It supplies a legal test that applies to every agency currently sitting on appropriated money while telling applicants that nothing can be done.

The timeline GAO reconstructed

What makes B-337872 forceful is that it is built almost entirely from the agency's own calendar and ledger.

• February 11, 2025 — a presidential executive order directs agencies to prepare for workforce reduction.
• March 27, 2025 — HHS announces a reorganization folding AHRQ into the Office of the Assistant Secretary for Planning and Evaluation.
• April 1, 2025 — the reduction in force is announced. AHRQ's grant obligations for that month total $191,795.
• May 2025 — grant obligations are zero. Peer review meetings scheduled for May and June are cancelled.
• July 14, 2025 — more than 120 AHRQ employees are formally separated.
• September 1, 2025 — roughly 60 percent of the appropriation is obligated, against 89 percent at the same point in fiscal year 2024.
• September 29, 2025 — a federal court orders AHRQ to preserve $70 million.
• September 30, 2025 — the fiscal year ends with more than $78 million unobligated.

Of the unobligated balance, GAO identifies roughly $75 million tied to 185 grants that had cleared review and were awaiting award.

The three-part test, and why each part matters to you

GAO's analysis runs through three questions in sequence. If you are a grantee or an applicant trying to assess whether your own agency's silence is lawful, these are the three questions to ask.

1. Was money actually withheld?

An agency with a lump-sum appropriation has genuine discretion over how to allocate it. AHRQ's enabling statute under the Public Health Service Act mandates some awards and permits others, and the agency may shift emphasis among permissible purposes. If AHRQ had slowed grants while accelerating research contracts, that would be allocation, not withholding.

GAO checked. It did not happen. Obligations for research contracts and other categories declined proportionally alongside grants. Nothing was redirected; the money simply stopped moving.

This is the single most portable part of the decision. Reallocation is a defense. Across-the-board slowdown is not. When an agency tells you its priorities have shifted, the testable claim is whether the money shifted with them.

2. Was it an impoundment or a programmatic delay?

This is the heart of the case. "Programmatic delay" is the recognized category for an agency that misses a spending window for genuine operational reasons — a statutory review requirement, an unfinished environmental assessment, a contractor that failed to deliver. Programmatic delay is lawful. Impoundment is not.

HHS argued programmatic delay: the Public Health Service Act requires peer review, peer review did not happen, and so awards could not issue.

GAO rejected it on the evidence. The peer review sessions were not overwhelmed — they were affirmatively cancelled. No notices for replacement review meetings were posted. The Director of AHRQ's Office of Extramural Research, Education, and Priority Populations acknowledged in a declaration that the office could not process awards, with a single director remaining in place. And there was no plan to resume.

GAO's formulation — that the elective decision to remove substantial grant administration personnel cannot be offered as an unavoidable delay — closes the loop. You cannot manufacture the operational obstacle and then plead it. An agency that dismantles its own award machinery owns the consequence.

3. Did the agency follow the Act?

The Impoundment Control Act gives the President a lawful path to not spend money: submit a special message to Congress proposing a temporary deferral or a permanent rescission, and let Congress respond. HHS submitted no such message. The September 29 court order protected the withholding that followed it, but, as GAO notes, it does nothing to justify the five months that preceded it.

GAO also disposed of a secondary argument worth knowing: committee report language is not binding unless the statute incorporates it. Agencies cite report language both ways, and this decision confirms that it does not create obligations and does not excuse them either.

What happened next, in the numbers

The fiscal 2025 shortfall was the beginning, not the end. AHRQ grant spending by fiscal year:

That is a 90 percent decline over two years, against a workforce that lost roughly 80 percent of its people. The practical reality for health services researchers is that AHRQ has largely stopped making grants, and many of its surviving program announcements expired in place during the spring of 2026 rather than being competed.

This matters for how you read the decision. B-337872 adjudicates fiscal 2025. The fiscal 2026 numbers are worse, and they are not covered by it.

Why a GAO decision is not a check in the mail

GAO is Congress's auditor, not a court. The decision contains no remedy and no order. Its stated function is to report the violation so Congress can exercise the power of the purse.

There are two live escalation paths. First, the Comptroller General has statutory authority to bring a civil action to compel the obligation of improperly withheld funds — rarely used, but available. Second, separate litigation under the Administrative Procedure Act, Society of General Internal Medicine v. HHS, is pursuing the same facts on different legal theories, and it was that case that produced the September 29 order preserving $70 million.

AcademyHealth's president, Aaron Carroll, put the realistic frame on it: the ruling matters only if it produces congressional action. Senator Patty Murray and Representatives Diana DeGette and Don Beyer have called for exactly that, with fiscal 2026 AHRQ funding as the lever.

For an individual researcher whose award died in the spring 2025 freeze, the honest answer is that this decision does not revive it. Fiscal 2025 funds have expired. What the decision does is convert an anecdote into a formal legal finding — which is the raw material oversight runs on, and which is admissible in a way that frustration is not.

The pattern this fits into

B-337872 is not isolated. GAO reached a parallel conclusion on EPA's Community Change Grants in B-337485, and the broader fiscal year produced a set of agencies holding appropriated money at year end:

• NSF closed fiscal 2026 with more than $1 billion unobligated and roughly $1.7 billion carrying into fiscal 2027, obligating $6.4 billion against $8.3 billion the prior year, across 6,218 awards versus 8,647.
• NIH, by contrast, spent essentially its entire $34 billion extramural budget — while issuing its fewest awards in six years, a product of front-loading multiyear commitments rather than withholding.

Those are three different mechanisms producing a similar felt experience. Only one of them is an impoundment. The distinction is not pedantic: it determines whether the answer is litigation, appropriations language, or simply adjusting your submission calendar. We have written about the broader set of ways money disappears after Congress appropriates it in Five Ways Federal Grants Get Killed After Congress Funds Them and about the unspent-appropriations pattern in The Science Funding Paradox.

Four things to do with this decision

Document the obligation gap, not the vibe. The decision turned on comparative obligation rates — 60 percent versus 89 percent at the same calendar point. If you are building a case that an agency is sitting on money, that comparison is the artifact that persuades. Agency spend plans and USAspending obligation data are public.

Test the reallocation claim. An agency that says its priorities changed should be able to show money moving toward the new priority. If every category fell together, the priority story does not hold, and GAO has now said so in writing.

Ask whether the obstacle was chosen. Cancelled review panels with no replacement notices, no posted plan to resume, and a staffing decision that preceded the delay are the exact fact pattern GAO found dispositive. These are observable from outside the agency.

Do not plan your fiscal 2027 submissions around a reversal. AHRQ's fiscal 2026 grant spending was $41.3 million. Even a favorable congressional response takes months and will not restore expired-year funds. Treat AHRQ as a diminished channel and identify alternative homes for health services research — NIH institutes with delivery-science portfolios, PCORI, and state and foundation funders — while the oversight process runs its course.

The deeper takeaway is narrower than the headline and more useful. Appropriated money is not optional, a lump sum is not a license to spend nothing, and an agency cannot cite a shortage it created as the reason it could not act. That is now a documented legal conclusion rather than an argument, and it applies well beyond one small agency in Rockville.

Sources: GAO B-337872 · Inside Higher Ed · The Hill · GAO B-337485 (EPA) · AIP Science Policy, October 5, 2026